Indication: Leukemia

A randomized trial of Sirolimus-based graft versus host disease prophylaxis after Hematopoietic Stem Cell transplantation in selected subjects with CR1 adn CR2 (ALL).

Sub-indication: Leukemia

Drug

Principal Investigator: Alexandra Cheerva, M.D.
Norton Children's Cancer Institute, affiliated with the UofL School of Medicine

Sponsor: Children's Oncology Group (COG)

Search our entire site.